A phase II, multicenter study of decitabine (5-aza-2'deoxycytidine) in chronic myelogenous leukemia blast phase refractory to imatinib mesylate (STI 571).
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2009
At a glance
- Drugs Decitabine (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 09 Sep 2009 Eisai Inc added as sponsor instead of MGI pharma as MGI pharma was taken over by Eisai Inc.
- 21 Sep 2006 Status change
- 06 Sep 2005 New trial record.